Peptide and Oligonucleotide CDMO Market: Trends, Growth Drivers, and Future Outlook Through 2034
- shubham3872
- 10 minutes ago
- 4 min read
The rapid advancement of precision medicine and next-generation therapeutics has significantly increased demand for specialized manufacturing capabilities across the biopharmaceutical industry. As the peptide contract manufacturing market expands and oligonucleotide manufacturing services become increasingly essential for RNA- and DNA-based therapies, pharmaceutical companies are relying more heavily on CDMO pharmaceutical outsourcing to accelerate drug development and commercialization. These trends are fueling the growth of the Peptide and Oligonucleotide CDMO Market, as contract development and manufacturing organizations (CDMOs) provide the technical expertise, scalable infrastructure, and regulatory support required for the production of complex therapeutic molecules.
The Peptide and Oligonucleotide CDMO Market was valued at USD 3.5 billion in 2024 and is projected to grow from USD 4.0 billion in 2025 to USD 14.2 billion by 2034, registering a robust CAGR of 15.1% during the forecast period (2025–2034).
Rising Demand for Peptide Contract Manufacturing
The peptide contract manufacturing market has grown rapidly due to the increasing use of peptide-based therapeutics for treating metabolic disorders, cancer, infectious diseases, and endocrine conditions. Peptides offer high target specificity, favorable safety profiles, and reduced off-target effects, making them attractive candidates for modern drug development.
Manufacturing peptide therapeutics requires sophisticated synthesis technologies, purification processes, and strict quality control standards. Many pharmaceutical and biotechnology companies choose to partner with CDMOs rather than invest in expensive in-house production facilities. Outsourcing enables developers to reduce capital expenditure, shorten development timelines, and access specialized expertise throughout clinical and commercial manufacturing.
As the number of peptide drug candidates entering clinical trials continues to increase, demand for advanced contract manufacturing services is expected to remain strong.
Expanding Role of Oligonucleotide Manufacturing Services
Oligonucleotide manufacturing services have become a critical component of modern pharmaceutical production, particularly with the rapid adoption of RNA therapeutics, antisense oligonucleotides, siRNA, mRNA technologies, and gene-editing applications.
Manufacturing oligonucleotides involves complex chemical synthesis, purification, analytical testing, and stringent regulatory compliance. CDMOs provide comprehensive end-to-end solutions that support every stage of product development, from process optimization to commercial-scale manufacturing.
Key services include:
Custom oligonucleotide synthesis
Process development and scale-up
GMP manufacturing
Analytical method development
Quality assurance and regulatory documentation
The growing success of nucleic acid-based medicines and personalized therapies continues to drive investment in oligonucleotide manufacturing capacity worldwide.
CDMO Pharmaceutical Outsourcing Accelerating Drug Development
The increasing popularity of CDMO pharmaceutical outsourcing is reshaping the pharmaceutical manufacturing landscape. Outsourcing allows drug developers to leverage specialized manufacturing expertise while focusing internal resources on research, innovation, and commercialization.
Leading CDMOs offer integrated services covering:
Drug substance development
Clinical trial material production
Commercial manufacturing
Fill-finish operations
Packaging and regulatory support
This integrated approach improves operational efficiency, reduces manufacturing risks, and accelerates time-to-market for innovative therapeutics.
As regulatory requirements become more complex and therapeutic modalities continue to evolve, pharmaceutical companies increasingly rely on strategic outsourcing partnerships to remain competitive.
Growth Drivers of the Peptide and Oligonucleotide CDMO Market
The global Peptide and Oligonucleotide CDMO Market is experiencing robust growth due to several important factors:
Rising demand for peptide and nucleic acid therapeutics
Growth of precision medicine and targeted therapies
Increasing pharmaceutical outsourcing activities
Expansion of clinical pipelines for RNA-based drugs
Rising investments in biotechnology research
Growing need for GMP-compliant manufacturing facilities
The increasing prevalence of chronic diseases and rare genetic disorders has further accelerated the development of innovative peptide and oligonucleotide therapies, creating sustained demand for specialized CDMO services.
Additionally, smaller biotechnology companies frequently depend on outsourcing partners to access advanced manufacturing technologies without making significant capital investments.
Discover the Complete Report Here:
Some of the major players operating in the global peptide and oligonucleotide CDMO market include:
Aurigene Pharmaceutical Services Ltd.
Bachem Group
CordenPharma
Creative Peptides
Curia Global, Inc.
EUROAPI
Genscript Biotech Corporation
Lonza Group
Merck KGaA
PolyPeptide Group
Senn Chemicals AG
STA Pharmaceutical Co. Ltd.
Sylentis, S.A.
Thermo Fisher Scientific Inc.
Wuxi AppTec
Regional Market Outlook
North America currently dominates the Peptide and Oligonucleotide CDMO Market, supported by a strong biotechnology ecosystem, significant pharmaceutical R&D investment, and well-established regulatory infrastructure. Europe also maintains a substantial market share due to increasing demand for advanced biologics and growing CDMO capacity.
Meanwhile, the Asia-Pacific region is expected to experience the fastest growth during the forecast period. Countries such as China, India, South Korea, and Singapore are expanding their pharmaceutical manufacturing capabilities, supported by lower production costs, skilled workforces, and favorable government initiatives promoting biotechnology innovation.
Future Outlook
The future of the Peptide and Oligonucleotide CDMO Market will be shaped by continued advances in precision medicine, gene therapies, RNA therapeutics, and personalized healthcare. As pharmaceutical companies increasingly prioritize flexible manufacturing models, demand for high-quality CDMO services will continue to grow.
Investment in next-generation manufacturing technologies, expanded GMP facilities, and sustainable production practices will further enhance the competitiveness of CDMOs operating in this rapidly evolving market.
Conclusion
The growing Peptide and Oligonucleotide CDMO, expanding oligonucleotide manufacturing services, and increasing adoption of CDMO pharmaceutical outsourcing are transforming the pharmaceutical manufacturing industry. As demand for peptide- and nucleic acid-based therapies continues to rise, the Peptide and Oligonucleotide CDMO Market is positioned for sustained growth. Through advanced manufacturing technologies, regulatory expertise, and scalable production capabilities, CDMOs will remain essential partners in bringing innovative therapies to patients worldwide.
More Trending Latest Reports By Polaris Market Research:
Comments